Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 2011; 105(05): 931-932
DOI: 10.1160/TH10-11-0757
DOI: 10.1160/TH10-11-0757
Letters to the Editor
An activated protein C-dependent thrombin generation assay predicts chemotherapy-associated venous thromboembolism in cancer patients
Authors
Financial support: This work was partially supported by the Italian Ministry of Health Grants RFPS-2006–7–342220 and ACC-WP 3/1b.
Further Information
Publication History
Received:
25 November 2010
Accepted after minor revision:
28 January 2011
Publication Date:
28 November 2017 (online)
-
References
- 1 Di Nisio M, Ferrante N, De Tursi M. et al. Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Thromb Haemost 2010; 104: 1049-1054.
- 2 Ferroni P, Formica V, Roselli M. et al. Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs. Curr Vasc Pharmacol 2010; 8: 102-113.
- 3 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 381S-453S.
- 4 Khorana AA, Streiff MB, Farge D. et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009; 27: 4919-4926.
- 5 Khorana AA, Kuderer NM, Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111: 4902-4907.
- 6 Eichinger S, Heinze G, Jandeck LM. et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism. The Vienna Prediction Model. Circulation 2010; 121: 1630-1636.
- 7 Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27: 4839-4847.
- 8 Sousou T, Khorana AA. New insights into cancer-associated thrombosis. Arterioscler Thromb Vasc Biol 2009; 29: 316-320.
- 9 Douma RA, van Sluis GL, Kamphuisen PW. et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost 2010; 104: 831-836.
- 10 Tripodi A, Legnani C, Lemma L. et al. Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. J Thromb Thrombolysis 2010; 30: 215-219.
- 11 Toulon P, Smirnov M, Triscott M. et al. A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. Thromb Res 2009; 124: 137-143.
- 12 Lyman GH. Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer. Cancer 2009; 115: 5637-5650.